겸상적혈구증 치료 시장 : 질환별, 치료법별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2023-2030년)

Sickle Cell Disease Treatment Market with COVID-19 Impact Analysis, By Disease, By Treatment, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030

US $ 3,250 ￦ 4,456,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,650 ￦ 6,375,000

PDF (5 User License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,650 ￦ 7,746,000

PDF & Excel (Enterprise User License)

PDF & Excel 보고서를 동일 기업 내 모든 사용자가 사용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

보고서 주요 내용

겸상적혈구증 치료 시장 규모는 2022년 10억 1,070만 달러로 2023년부터 2030년까지 CAGR 30.8%로 확대

겸상적혈구증 치료 시장 - 시장 역학:

• 신약의 혁신이 시장 성장을 주도합니다.
• 20년 만에 영국에서 겸상적혈구증에 대한 새로운 치료제가 발견되었습니다. BBC에 따르면 노바티스가 생산하는 크리잔리주맙은 "혁신적인 치료법"으로 불리며, 정맥에 주사하여 단독으로 사용하거나 정기적인 수혈 및 기존 치료와 함께 사용할 수 있다고 합니다. 한 연구에 따르면 크리잔리주맙을 사용한 환자들은 연간 평균 1.6회 겸상적혈구 위기를 경험했는데, 이는 평소 연간 3회에 가까운 횟수에서 감소했습니다. 크리잔리주맙은 16세 이상 겸상적혈구 빈혈 환자의 혈관 폐쇄성 위기 발생률을 낮추기 위해 사용됩니다. 겸상적혈구빈혈증 치료제 시장은 이러한 획기적인 치료제의 발명으로 인해 확대되고 있습니다.

겸상적혈구증 치료 시장 - 세분화 분석:

• 세계 겸상적혈구증 치료 시장은 질병, 치료법, 지역별로 분류됩니다.
• 질병에 따라 세계 겸상적혈구 질환 치료제 시장은 겸상적혈구 빈혈, 겸상적혈구 c 질환, 겸상적혈구 β- 지중해 빈혈, 기타로 세분화됩니다. 겸상 적혈구 빈혈 부문은 예측 기간 동안 가장 높은 CAGR로 성장할 것으로 예상됩니다. 이러한 성장은 유전자 돌연변이로 인한 겸상적혈구빈혈증 환자의 증가에 따른 것으로, 11번 염색체에 존재하는 헤모글로빈 베타 유전자의 돌연변이가 겸상적혈구증후군의 원인이 됩니다. 겸상 적혈구 빈혈의 적혈구는 결함이 있는 헤모글로빈으로 인해 딱딱하고 끈적끈적하며 기형적입니다. 겸상 적혈구 빈혈의 유전 적 유병률은이 시장의 확장을 가속화하고 있습니다.
• 치료법에 따라 세계 시장은 수혈, 약물 치료, 골수 이식으로 구분됩니다. 예측 기간 동안 수혈 분야가 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 겸상적혈구증 치료에 수혈을 많이 사용하는 것이 이러한 상승의 원인입니다. 급성 흉부 증후군(ACS) 치료에는 단순 수혈(ST)과 자동 적혈구 교환(RCE)이 모두 사용됩니다. 겸상적혈구증 환자에게 자주 발생하는 뇌졸중 치료에 수혈의 사용이 증가하면서 시장 확대에 박차를 가하고 있습니다.

겸상적혈구증 치료 시장 - 지리적 인사이트:

지역적으로 이 시장은 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에 분포되어 있습니다. 이 지역은 비지니스를 가져오는 국가에 따라 더 세분화됩니다. 예측 기간 동안 북미가 시장을 지배할 것으로 보입니다. 이 지역의 시장 매출 성장은 주로 겸상적혈구증 치료의 상당한 발전과 치료 옵션에 대한 접근성 향상에 기인합니다. 이 지역의 높은 가처분 소득도 시장 수익 성장의 주요 요인입니다. 가장 높은 매출 점유율을 차지하는 것은 미국 시장이며, 이는 정부 지원의 증가에 기인합니다. 또한, 현지 시장 기업들은 제품 라인업을 다양화하고 세계 입지를 구축하기 위해 제휴 및 인수를 추진하고 있습니다. 예를 들어, 2022년 화이자와 세계혈액치료제(World Blood Therapeutics)는 혈액학 제품 포트폴리오를 늘리기 위한 거래에 합의했습니다.

겸상적혈구증 치료 시장 - 경쟁 상황:

시장에 진출한 주요 기업은 Medunik USA, Bristol Myers Squibb Co., Emmaus Medical Inc., Addmedica, Novartis AG, Global Blood Therapeutics Inc., Sanofi SA, Bluebird Biotechnology, Pfizer Inc., Aruvant Sciences Inc., Glycomimetics Inc., Editas Medicine Inc., CRISPR Therapeutic입니다.

목차

제1장 겸상적혈구증 치료 시장 개요

• 조사 범위
• 시장 추정 연수

제2장 주요 요약

• 시장 내역
• 경쟁 인사이트

제3장 겸상적혈구증 치료 주요 시장 동향

• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 향후 시장 동향

제4장 겸상적혈구증 치료 산업 조사

• PEST 분석
• Porter's Five Forces 분석
• 성장 전망 매핑
• 규제 체계 분석

제5장 겸상적혈구증 치료 시장 : COVID-19의 영향 분석

• 신종 코로나바이러스 감염증 이전의 영향 분석
• 신종 코로나바이러스 감염증 후의 영향 분석

제6장 겸상적혈구증 치료 시장 상황

• 겸상적혈구증 치료 시장 점유율 분석, 2022년
• 주요 제조업체별 내역 데이터
  • 기존 기업 분석
  • 신흥 기업 분석

제7장 겸상적혈구증 치료 시장 - 질환별

• 개요
  • 질환별 부문 점유율 분석
  • 겸상 적혈구 빈혈
  • 겸상 헤모글로빈 C병
  • 겸상 베타 지중해 빈혈
  • 기타

제8장 겸상적혈구증 치료 시장 - 치료별

• 개요
  • 치료별 부문 점유율 분석
  • 수혈
  • 약물요법
  • 골수 이식

제9장 겸상적혈구증 치료 시장 - 지역별

• 서론
• 북미
  • 개요
  • 북미의 주요 제조업체
  • 미국
  • 캐나다
• 유럽
  • 개요
  • 유럽의 주요 제조업체
  • 독일
  • 이탈리아
  • 영국
  • 프랑스
  • 러시아
  • 네덜란드
  • 스웨덴
  • 폴란드
  • 기타
• 아시아태평양(APAC)
  • 개요
  • 아시아태평양의 주요 제조업체
  • 인도
  • 중국
  • 일본
  • 한국
  • 호주
  • 태국
  • 인도네시아
  • 필리핀
  • 기타
• 라틴아메리카
  • 개요
  • 라틴아메리카의 주요 제조업체
  • 브라질
  • 멕시코
  • 아르헨티나
  • 콜롬비아
  • 기타
• 중동 및 아프리카
  • 개요
  • 중동 및 아프리카의 주요 제조업체
  • 사우디아라비아
  • 아랍에미리트
  • 이스라엘
  • 터키
  • 알제리
  • 이집트
  • 기타

제10장 주요 벤더 분석 - 겸상적혈구증 치료 산업

• 경쟁 대시보드
• 기업 개요
  • Medunik USA
  • Bristol Myers Squibb Co.
  • Emmaus Medical Inc.
  • Addmedica
  • Novartis AG
  • Global Blood Therapeutics Inc.
  • Sanofi SA
  • Bluebird Biotechnology
  • Pfizer Inc.
  • Aruvant Sciences Inc.
  • Glycomimetics Inc.
  • Editas Medicine Inc.
  • CRISPR Therapeutic

제11장 애널리스트의 전방위 전망

ksm

영문 목차

영문목차

REPORT HIGHLIGHT

Sickle Cell Disease Treatment Market size was valued at USD 1,010.7 Million in 2022, expanding at a CAGR of 30.8% from 2023 to 2030.

Hemoglobin, a protein that transports oxygen throughout the body, is impacted by sickle cell disease (SCD), a hereditary red blood cell (RBC) problem. Numerous consequences are brought on by it, including acute chest syndrome, anemia, and vaso-occlusive crisis (VOC). Currently, doctors frequently recommend bone marrow and blood transplants to treat SCD. It entails removing the damaged bone marrow and replacing it with healthy bone marrow obtained from a donor. As they can lessen particular symptoms and extend patients' lives, other efficient therapies including pharmaceuticals and blood transfusions are also being used.

Sickle Cell Disease Treatment Market- Market Dynamics:

• Innovation in novel medication drives the market growth.

• The first new treatment for sickle cell disease in 20 years has been discovered in the United Kingdom. Crizanlizumab, a drug produced by Novartis, has been referred to be "an innovative treatment." According to the BBC, it is injected into a vein and can be used alone or in conjunction with regular blood transfusions and conventional medical care. In a study, patients using crizanlizumab experienced a sickle-cell crisis 1.6 times year on average, down from nearly three times annually in the norm. A drug called crizanlizumab is used to reduce the incidence of vaso-occlusive crises in sickle cell anemia patients aged 16 and older. The Sickle Cell Disease Treatment Market is expanding as a result of these inventive breakthrough treatments.

Sickle Cell Disease Treatment Market- Key Insights:

• As per the analysis shared by our research analyst, the global Sickle Cell Disease Treatment market is estimated to grow annually at a CAGR of around 30.8% over the forecast period (2023-2030)

• The Sickle Cell Disease Treatment industry is projected to grow at a significant rate owing to the high incidence of sickle cell anemia disease

• Based on the disease, the sickle cell anaemia segment is expected to grow at the highest CAGR over the forecast period

• Based on the treatment, the blood transfusion segment is expected to capture the largest market share over the forecast period

• Based on region, North America is expected to dominate the market over the forecast period

Sickle Cell Disease Treatment Market- Segmentation Analysis:

• The Global Sickle Cell Disease Treatment Market is segmented based on disease, treatment, and Region.

• Based on disease, the global Sickle Cell Disease Treatment market is segmented into sickle cell anaemia, sickle haemoglobin c disease, sickle beta thalassemia, others. The sickle cell anaemia segment is expected to grow at the highest CAGR over the forecast period. This expansion is the result of an increase in sickle cell anemia patients brought on by a gene mutation. A mutation in the haemoglobin-Beta gene found on chromosome 11 causes sickle cell disease. Red blood cells in sickle cell anemia are hard, sticky, and malformed as a result of the defective hemoglobin. The prevalence of inheriting sickle cell anemia is accelerating this market's expansion.

• Based on treatment, the global market is segmented into blood transfusion, pharmacotherapy, bone marrow transplant. The blood transfusion segment is expected to capture the largest market share over the forecast period. The massive use of blood transfusion in the treatment of sickle cell disease is the cause of this rise. Acute chest syndrome (ACS) is treated with both simple transfusion (ST) of packed red blood cells and automated red cell exchange (RCE). The increasing use of blood transfusions in the treatment of stroke, which sickle cell disease patients commonly have, is fueling this market's expansion.

Sickle Cell Disease Treatment Market- Geographical Insights:

Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. North America is expected to dominate the market over the forecast period. The region's market revenue growth is primarily being driven by significant advancements in the treatment of sickle cell disease and widespread accessibility to treatment options. The high level of disposable income in this region is also a major driver of the expansion of market revenue. The highest revenue share came from the U.S. market as a result of rising government assistance. Additionally, local market players are joining forces and making acquisitions to diversify their product offerings and establish a worldwide presence. For instance, in 2022, Pfizer Inc. and Global Blood Therapeutics, Inc. reached a deal that will ultimately increase the hematology product portfolio.

Sickle Cell Disease Treatment Market- Competitive Landscape:

The key players operating in the market are Medunik USA, Bristol Myers Squibb Co., Emmaus Medical Inc., Addmedica, Novartis AG, Global Blood Therapeutics Inc, Sanofi SA, Bluebird Biotechnology, Pfizer Inc., Aruvant Sciences Inc., Glycomimetics Inc., Editas Medicine Inc. and CRISPR Therapeutic.

Recent Developments:

In February 2022, Global Blood Therapeutics Inc. was granted permission to sell Oxbryta for the treatment of sickle cell disease (SCD)-related hemolytic anemia in adults and children 12 years of age and older as a monotherapy or in combination with hydroxycarbamide.

Key features of the study:

• This proposed research study on Sickle Cell Disease Treatment market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year

• The report provides the client the latest up-to-date and trending insights about the Sickle Cell Disease Treatment market.

• The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Sickle Cell Disease Treatment market

• The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Sickle Cell Disease Treatment market

• Impact of COVID-19 on Sickle Cell Disease Treatment market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Sickle Cell Disease Treatment market post-COVID will also be covered.

• In order to give the users of this report a comprehensive view on the Sickle Cell Disease Treatment market, we have also included competitive landscape and key innovator analysis for the Sickle Cell Disease Treatment market.

• The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.

• The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Sickle Cell Disease Treatment market.

• In addition, the report also unveils the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.

• The global Sickle Cell Disease Treatment market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SICKLE CELL DISEASE TREATMENT MARKET KEY PLAYERS

• Medunik USA
• Bristol Myers Squibb Co.
• Emmaus Medical Inc.
• Addmedica
• Novartis AG
• Global Blood Therapeutics Inc.
• Sanofi SA
• Bluebird Biotechnology
• Pfizer Inc.
• Aruvant Sciences Inc.
• Glycomimetics Inc.
• Editas Medicine Inc.
• CRISPR Therapeutic

GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY DISEASE

• Sickle Cell Anaemia
• Sickle Haemoglobin C Disease
• Sickle Beta Thalassemia
• Others

GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY TREATMENT

• Blood Transfusion
• Pharmacotherapy
• Bone Marrow Transplant

GLOBAL SICKLE CELL DISEASE TREATMENT MARKET, BY REGION

• North America
• The U.S.
• Canada
• Europe
• Germany
• France
• Italy
• Spain
• United Kingdom
• Russia
• Netherlands
• Sweden
• Poland
• Rest of Europe
• Asia Pacific
• India
• China
• South Korea
• Japan
• Australia
• Thailand
• Indonesia
• Philippines
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• United Arab Emirates
• Israel
• Turkey
• Algeria
• Egypt
• Rest of MEA

Table of Contents

1. Sickle Cell Disease Treatment Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Sickle Cell Disease Treatment Market Snippet by Disease
  • 2.1.2. Sickle Cell Disease Treatment Market Snippet by Treatment
  • 2.1.3. Sickle Cell Disease Treatment Market Snippet by Country
  • 2.1.4. Sickle Cell Disease Treatment Market Snippet by Region
• 2.2. Competitive Insights

3. Sickle Cell Disease Treatment Key Market Trends

• 3.1. Sickle Cell Disease Treatment Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Sickle Cell Disease Treatment Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Sickle Cell Disease Treatment Market Opportunities
• 3.4. Sickle Cell Disease Treatment Market Future Trends

4. Sickle Cell Disease Treatment Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Sickle Cell Disease Treatment Market: COVID-19 Impact Analysis

• 5.1. Pre-COVID-19 Impact Analysis
• 5.2. Post-COVID-19 Impact Analysis
  • 5.2.1. Top Performing Segments
  • 5.2.2. Marginal Growth Segments
  • 5.2.3. Top Looser Segments
  • 5.2.4. Marginal Loss Segments

6. Sickle Cell Disease Treatment Market Landscape

• 6.1. Sickle Cell Disease Treatment Market Share Analysis, 2022
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Sickle Cell Disease Treatment Market - By Disease

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Disease, 2022 & 2030 (%)
  • 7.1.2. Sickle Cell Anaemia
  • 7.1.3. Sickle Haemoglobin C Disease
  • 7.1.4. Sickle Beta Thalassemia
  • 7.1.5. Others

8. Sickle Cell Disease Treatment Market - By Treatment

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Treatment, 2022 & 2030 (%)
  • 8.1.2. Blood Transfusion
  • 8.1.3. Pharmacotherapy
  • 8.1.4. Bone Marrow Transplant

9. Sickle Cell Disease Treatment Market- By Geography

• 9.1. Introduction
  • 9.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
• 9.2. North America
  • 9.2.1. Overview
  • 9.2.2. Sickle Cell Disease Treatment Key Manufacturers in North America
  • 9.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.2.4. North America Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
  • 9.2.5. North America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.2.6. U.S.
    • 9.2.6.1. Overview
    • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.2.6.3. U.S. Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.2.6.4. U.S. Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.2.7. Canada
    • 9.2.7.1. Overview
    • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.2.7.3. Canada Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.2.7.4. Canada Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
• 9.3. Europe
  • 9.3.1. Overview
  • 9.3.2. Sickle Cell Disease Treatment Key Manufacturers in Europe
  • 9.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.3.4. Europe Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
  • 9.3.5. Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.3.6. Germany
    • 9.3.6.1. Overview
    • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.6.3. Germany Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.3.6.4. Germany Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.3.7. Italy
    • 9.3.7.1. Overview
    • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.7.3. Italy Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.3.7.4. Italy Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.3.8. United Kingdom
    • 9.3.8.1. Overview
    • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.8.3. United Kingdom Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.3.8.4. United Kingdom Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.3.9. France
    • 9.3.9.1. Overview
    • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.9.3. France Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.3.9.4. France Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.3.10. Russia
    • 9.3.10.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.10.2. Russia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.3.10.3. Russia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.3.11. Netherlands
    • 9.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.11.2. Netherlands Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.3.11.3. Netherlands Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.3.12. Sweden
    • 9.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.12.2. Sweden Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.3.12.3. Sweden Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.3.13. Poland
    • 9.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.13.2. Poland Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.3.13.3. Poland Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.3.14. Rest of Europe
    • 9.3.14.1. Overview
    • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.3.14.3. Rest of the Europe Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.3.14.4. Rest of the Europe Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
• 9.4. Asia Pacific (APAC)
  • 9.4.1. Overview
  • 9.4.2. Sickle Cell Disease Treatment Key Manufacturers in Asia Pacific
  • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.4.4. Asia Pacific Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
  • 9.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.4.6. India
    • 9.4.6.1. Overview
    • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.6.3. India Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.4.6.4. India Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.4.7. China
    • 9.4.7.1. Overview
    • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.7.3. China Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.4.7.4. China Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.4.8. Japan
    • 9.4.8.1. Overview
    • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.8.3. Japan Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.4.8.4. Japan Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.4.9. South Korea
    • 9.4.9.1. Overview
    • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.9.3. South Korea Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.4.9.4. South Korea Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.4.10. Australia
    • 9.4.10.1. Overview
    • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.10.3. Australia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.4.10.4. Australia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.4.11. Thailand
    • 9.4.11.1. Overview
    • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.11.3. Thailand Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.4.11.4. Thailand Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.4.12. Indonesia
    • 9.4.12.1. Overview
    • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.12.3. Indonesia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.4.12.4. Indonesia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.4.13. Philippines
    • 9.4.13.1. Overview
    • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.13.3. Philippines Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.4.13.4. Philippines Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.4.14. Rest of APAC
    • 9.4.14.1. Overview
    • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.4.14.3. Rest of APAC Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.4.14.4. Rest of APAC Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
• 9.5. Latin America
  • 9.5.1. Overview
  • 9.5.2. Sickle Cell Disease Treatment Key Manufacturers in Latin America
  • 9.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.5.4. Latin America Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
  • 9.5.5. Latin America Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.5.6. Brazil
    • 9.5.6.1. Overview
    • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.6.3. Brazil Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.5.6.4. Brazil Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.5.7. Mexico
    • 9.5.7.1. Overview
    • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.7.3. Mexico Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.5.7.4. Mexico Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.5.8. Argentina
    • 9.5.8.1. Overview
    • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.8.3. Argentina Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.5.8.4. Argentina Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.5.9. Colombia
    • 9.5.9.1. Overview
    • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.9.3. Colombia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.5.9.4. Colombia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.5.10. Rest of LATAM
    • 9.5.10.1. Overview
    • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
• 9.6. Middle East and Africa
  • 9.6.1. Overview
  • 9.6.2. Sickle Cell Disease Treatment Key Manufacturers in Middle East and Africa
  • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
  • 9.6.4. Middle East and Africa Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
  • 9.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.6.6. Saudi Arabia
    • 9.6.6.1. Overview
    • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.6.7. United Arab Emirates
    • 9.6.7.1. Overview
    • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.7.3. United Arab Emirates Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.6.7.4. United Arab Emirates Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.6.8. Israel
    • 9.6.8.1. Overview
    • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.8.3. Israel Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.6.8.4. Israel Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.6.9. Turkey
    • 9.6.9.1. Overview
    • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.9.3. Turkey Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.6.9.4. Turkey Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.6.10. Algeria
    • 9.6.10.1. Overview
    • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.10.3. Algeria Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.6.10.4. Algeria Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.6.11. Egypt
    • 9.6.11.1. Overview
    • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.11.3. Egypt Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.6.11.4. Egypt Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)
  • 9.6.12. Rest of MEA
    • 9.6.12.1. Overview
    • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
    • 9.6.12.3. Rest of MEA Market Size and Forecast, By Disease, 2018 - 2030 (US$ Million)
    • 9.6.12.4. Rest of MEA Market Size and Forecast, By Treatment, 2018 - 2030 (US$ Million)

10. Key Vendor Analysis- Sickle Cell Disease Treatment Industry

• 10.1. Competitive Dashboard
• 10.2. Company Profiles
  • 10.2.1. Medunik USA
  • 10.2.2. Bristol Myers Squibb Co.
  • 10.2.3. Emmaus Medical Inc.
  • 10.2.4. Addmedica
  • 10.2.5. Novartis AG
  • 10.2.6. Global Blood Therapeutics Inc.
  • 10.2.7. Sanofi SA
  • 10.2.8. Bluebird Biotechnology
  • 10.2.9. Pfizer Inc.
  • 10.2.10. Aruvant Sciences Inc.
  • 10.2.11. Glycomimetics Inc.
  • 10.2.12. Editas Medicine Inc.
  • 10.2.13. CRISPR Therapeutic

11. 360 Degree Analyst View

12. Appendix

• 12.1. Research Methodology
• 12.2. References
• 12.3. Abbreviations
• 12.4. Disclaimer
• 12.5. Contact Us

관련자료